Mecasermin Tercica.

Autores
Categoría Estudio primario
RevistaCurrent opinion in investigational drugs (London, England : 2000)
Año 2006

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
Tercica, under license from Genentech, has developed and launched mecasermin, recombinant human insulin-like growth factor-1 (rhIGF-1), for the treatment of growth failure in children with primary IGF deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.
Epistemonikos ID: e344f46c10454941c94e28830a55bcab80df4e9c
First added on: Oct 01, 2023